share_log

Moderna | 10-Q: Q3 2024 Earnings Report

Moderna | 10-Q: Q3 2024 Earnings Report

Moderna | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/08 05:11

Moomoo AI 已提取核心訊息

Moderna reported Q3 2024 revenue of $1.8 billion, including $1.8 billion in product sales primarily from COVID-19 vaccines and initial RSV vaccine sales. The company achieved net income of $13 million or $0.03 per share, compared to a net loss of $3.6 billion in Q3 2023. Cost of sales decreased significantly to $514 million or 28% of net product sales, down from 128% in the prior year period.The company's financial position remains strong with $9.2 billion in cash and investments as of September 30, 2024. Operating expenses showed improvement with research and development costs decreasing 2% to $1.1 billion and selling, general and administrative expenses declining 36% to $281 million compared to Q3 2023, reflecting enhanced operational efficiency and cost discipline.Looking ahead, Moderna expects continued transition to a seasonal commercial model for COVID-19 vaccines while expanding its product portfolio with the recent RSV vaccine launch. The company is advancing multiple late-stage clinical programs including next-generation COVID-19, seasonal flu, CMV and norovirus vaccines, as well as its individualized neoantigen therapy program in collaboration with Merck.
Moderna reported Q3 2024 revenue of $1.8 billion, including $1.8 billion in product sales primarily from COVID-19 vaccines and initial RSV vaccine sales. The company achieved net income of $13 million or $0.03 per share, compared to a net loss of $3.6 billion in Q3 2023. Cost of sales decreased significantly to $514 million or 28% of net product sales, down from 128% in the prior year period.The company's financial position remains strong with $9.2 billion in cash and investments as of September 30, 2024. Operating expenses showed improvement with research and development costs decreasing 2% to $1.1 billion and selling, general and administrative expenses declining 36% to $281 million compared to Q3 2023, reflecting enhanced operational efficiency and cost discipline.Looking ahead, Moderna expects continued transition to a seasonal commercial model for COVID-19 vaccines while expanding its product portfolio with the recent RSV vaccine launch. The company is advancing multiple late-stage clinical programs including next-generation COVID-19, seasonal flu, CMV and norovirus vaccines, as well as its individualized neoantigen therapy program in collaboration with Merck.
Moderna報告了2024年第三季度的營業收入爲$18億，包括來自COVID-19生物-疫苗和初始RSV生物-疫苗銷售的$18億產品銷售。該公司實現了凈利潤爲$1300萬，或者每股$0.03，而2023年第三季度則出現了$36億的淨虧損。銷售成本大幅下降至$51400萬，佔淨產品銷售的28%，而去年同期爲128%。截至2024年9月30日，該公司的財務狀況依然強勁，現金和投資達到$92億。營業費用有所改善，研發費用下降了2%，降至$11億，而銷售、一般和行政費用相比2023年第三季度下降了36%，降至$28100萬，反映出提升的運營效率和成本控制。展望未來，Moderna預計COVID-19生物-疫苗將持續向季節性商業模式轉型，同時通過最近的RSV生物-疫苗發佈擴展其產品組合。該公司正在推進多個晚期臨牀項目，包括下一代COVID-19、生物-疫苗、季節性流感、CMV和諾如病毒生物-疫苗，以及與默沙東合作的個性化新抗原療法項目。
Moderna報告了2024年第三季度的營業收入爲$18億，包括來自COVID-19生物-疫苗和初始RSV生物-疫苗銷售的$18億產品銷售。該公司實現了凈利潤爲$1300萬，或者每股$0.03，而2023年第三季度則出現了$36億的淨虧損。銷售成本大幅下降至$51400萬，佔淨產品銷售的28%，而去年同期爲128%。截至2024年9月30日，該公司的財務狀況依然強勁，現金和投資達到$92億。營業費用有所改善，研發費用下降了2%，降至$11億，而銷售、一般和行政費用相比2023年第三季度下降了36%，降至$28100萬，反映出提升的運營效率和成本控制。展望未來，Moderna預計COVID-19生物-疫苗將持續向季節性商業模式轉型，同時通過最近的RSV生物-疫苗發佈擴展其產品組合。該公司正在推進多個晚期臨牀項目，包括下一代COVID-19、生物-疫苗、季節性流感、CMV和諾如病毒生物-疫苗，以及與默沙東合作的個性化新抗原療法項目。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Nkarta
    NKTX
    -- 1.970
    Soleno Therapeutics
    SLNO
    -- 67.3900
    NuCana
    NCNA
    -- 1.0700
    ImmunityBio
    IBRX
    -- 3.360
    Marker Therapeutics
    MRKR
    -- 1.3700
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點